Effect of gene environment interactions on lung function and cardiovascular disease in COPD

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 277-287

  Hackett, Tillie Louise ^a   Stefanowicz, Dorota ^a   Aminuddin, Farzian ^a   Sin, Don D ^a   Connett, John E ^b   Anthonisen, Nicholas R ^c   Paré, Peter D ^a   Sandford, Andrew J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cardiovascular disease; Chronic obstructive pulmonary disease; Forced expiratory volume in one second; Gene environment interactions; Interleukin 6

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; IL1RN PROTEIN, HUMAN; IL6 PROTEIN, HUMAN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; FEMALE; FORCED EXPIRATORY VOLUME; GAMMA INTERFERON GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; INTERLEUKIN 1 RECEPTOR ANTAGONIST GENE; INTERLEUKIN 1BETA GENE; INTERLEUKIN 6 GENE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MUTATOR GENE; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CANADA; CLINICAL TRIAL; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; LUNG; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHENOTYPE; RISK ASSESSMENT; RISK FACTOR; SMOKING; STATISTICAL MODEL; TIME;

ADULT; CANADA; CARDIOVASCULAR DISEASES; FEMALE; FORCED EXPIRATORY VOLUME; GENE FREQUENCY; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; INTERLEUKIN-6; LINEAR MODELS; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; LUNG; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; SMOKING; TIME FACTORS;

EID: 84856389499     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S18279     Document Type: Article

References (62)

1. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet. 2003;362(9387):847-852.
2. Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: A case-control study. Lancet. 2006;368(9536):647-658.
3. Garantziotis S, Schwartz DA. Ecogenomics of respiratory diseases of public health significance. Annu Rev Public Health. 2010;31:37-51.
4. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165-1185.
5. He JQ, Foreman MG, Shumansky K, et al. Associations of IL6 polymorphisms with lung function decline and COPD. Thorax. 2009;64(8): 698-704.
6. He JQ, Burkett K, Connett JE, Anthonisen NR, Paré PD, Sandford AJ. Interferon gamma polymorphisms and their interaction with smoking are associated with lung function. Hum Genet. 2006;119(4):365-375.
7. Joos L, McIntyre L, Ruan J, et al. Association of IL-1beta and IL-1 receptor antagonist haplotypes with rate of decline in lung function in smokers. Thorax. 2001;56(11):863-866.
8. Anthonisen NR, Connett JE, Kiley J P, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272(19): 1497-1505.
9. Enright PL, Connett JE, Kanner RE, Johnson LR, Lee W W. Spirometry in the Lung Health Study. 1. Methods and quality control. Am Rev Respir Dis. 1991;143(6):1215-1223.
10. American Thoracic Society. Standardization of spirometry - 1987 update. Statement of the American Thoracic Society. Am Rev Respir Dis. 1987;136(5):1285-1298.
11. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: A randomized clinical trial. Ann Intern Med. 2005;142(4):233-239.
12. Jha HC, Divya A, Prasad J, Mittal A. Plasma circulatory markers in male and female patients with coronary artery disease. Heart Lung. 2010;39(4):296-303.
13. Isoda K, Ohsuzu F. The effect of interleukin-1 receptor antagonist on arteries and cholesterol metabolism. J Atheroscler Thromb. 2006;13(1): 21-30.
14. Guillén I, Blanes M, Gómez-Lechón MJ, Castell J V. Cytokine signaling during myocardial infarction: Sequential appearance of IL-1 beta and IL-6. Am J Physiol. 1995;269(2 Pt 2):R229-R235.
15. Patti G, D'Ambrosio A, Mega S, et al. Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction. J Am Coll Cardiol. 2004;43(1):35-38.
16. Miyao Y, Yasue H, Ogawa H, et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J. 1993;126(6): 1299-1304.
17. Cesari M, Penninx B W, Newman AB, et al. Infammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). Am J Cardiol. 2003;92(5):522-528.
18. Gaunt TR, Rodriguez S, Day IN. Cubic exact solutions for the estimation of pairwise haplotype frequencies: Implications for linkage disequilibrium analyses and a web tool 'CubeX'. BMC Bioinformatics. 2007;8:428.
19. Carter K W, McCaskie PA, Palmer LJ. SimHap GUI: An intuitive graphical user interface for genetic association analysis. BMC Bioinformatics. 2008;9:557.
20. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 2004;74(4):765-769.
21. Clay FE, Tarlow JK, Cork MJ, Cox A, Nicklin MJ, Duff G W. Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specifc mRNA assessment. Hum Genet. 1996;97(6):723-726.
22. De Torres J P, Pinto-Plata V, Casanova C, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest. 2008;133(6):1336-1343.
23. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway infammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(1):71-78.
24. Hurst JR, Donaldson GC, Perera WR. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(8):867-874.
25. Wilkinson TM, Hurst JR, Perera WR, Wilks M, Donaldson GC, Wedzicha JA. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest. 2006;129(2): 317-324.
26. Yende S, Waterer G W, Tolley EA, et al. Infammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax. 2006;61(1): 10-16.
27. Broekhuizen R, Wouters E F, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax. 2006;61(1):17-22.
28. Kuhn C 3rd, Homer RJ, Zhu Z, et al. Airway hyperresponsiveness and airway obstruction in transgenic mice. Morphologic correlates in mice overexpressing interleukin (IL)-11 and IL-6 in the lung. Am J Respir Cell Mol Biol. 2000;22(3):289-295.
29. Yanbaeva DG, Dentener MA, Spruit MA, et al. IL6 and CRP hap-lotypes are associated with COPD risk and systemic infammation: A case-control study. BMC Med Genet. 2009;10:23.
30. Córdoba-Lanús E, de Torres J P, López-Aguilar C, et al. Association of IL-6 gene polymorphisms and COPD in a Spanish population. Respir Med. 2008;102(12):1805-1811.
31. Seifart C, Dempfe A, Plagens A, et al. TNF-alpha-, TNF-beta-, IL-6-, and IL-10-promoter polymorphisms in patients with chronic obstructive pulmonary disease. Tissue Antigens. 2005;65(1):93-100.
32. Hogg JC. Pathophysiology of airfow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364(9435):709-721.
33. Wang Z, Zheng T, Zhu Z, et al. Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Exp Med. 2000;192(11): 1587-1600.
34. Trajkov D, Mirkovska-Stojkovikj J, Petlichkovski A, et al. Association of cytokine gene polymorphisms with chronic obstructive pulmonary disease in Macedonians. Iran J Allergy Asthma Immunol. 2009;8(1): 31-42.
35. Anthonisen NR, Connett JE, Enright PL, Manfreda J; Lung Health Study Research Group, Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002;166(3): 333-339.
36. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and futicasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
37. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: A population-based study and a systematic review of the literature. Chest. 2005;127(6):1952-1959.
38. McNicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnea: Overlaps in pathophysiology, systemic infammation, and cardiovascular disease. Am J Respir Crit Care Med. 2009;180(8): 692-700.
39. Vernooy JH, Küçükaycan M, Jacobs JA, et al. Local and systemic infammation in patients with chronic obstructive pulmonary disease: Soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med. 2002;166(9):1218-1224.
40. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. Chest. 2007;131(5):1557-1566.
41. Brozyna S, Ahern J, Hodge G, et al. Chemotactic mediators of Th1 T-cell traffcking in smokers and COPD patients. COPD. 2009;6(1): 4-16.
42. MacCallum PK. Markers of hemostasis and systemic infammation in heart disease and atherosclerosis in smokers. Proc Am Thorac Soc. 2005;2(1):34-43.
43. Mayosi BM, Avery PJ, Baker M, et al. Genotype at the -174G/C polymorphism of the interleukin-6 gene is associated with common carotid artery intimal-medial thickness: family study and meta-analysis. Stroke. 2005;36(10):2215-2219.
44. Brull DJ, Montgomery HE, Sanders J, et al. Interleukin-6 gene -174 g. c and -572 g. c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol. 2001;21(9):1458-1463.
45. Podgoreanu M V, Schwinn DA. New paradigms in cardiovascular medicine: Emerging technologies and practices: Perioperative genomics. J Am Coll Cardiol. 2005;46(11):1965-1977.
46. Jenny NS, Tracy R P, Ogg MS, et al. In the elderly, interleukin-6 plasma levels and the -174G. C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2002;22(12):2066-2071.
47. Walston JD, Fallin MD, Cushman M, et al. IL-6 gene variation is associated with IL-6 and C-reactive protein levels but not cardiovascular outcomes in the Cardiovascular Health Study. Hum Genet. 2007;122(5): 485-494.
48. Carty CL, Heagerty P, Heckbert SR, et al. Interaction between fbrino-gen and IL-6 genetic variants and associations with cardiovascular disease risk in the Cardiovascular Health Study. Ann Hum Genet. 2010; 74(1):1-10.
49. Fried L P, Borhani NO, Enright P, et al. The Cardiovascular Health Study: Design and rationale. Ann Epidemiol. 1991;1(3):263-276.
50. van Eeden SF, Yeung A, Quinlam K, Hogg JC. Systemic response to ambient particulate matter: Relevance to chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(1):61-67.
51. Helmersson J, Larsson A, Vessby B, Basu S. Active smoking and a history of smoking are associated with enhanced prostaglandin F(2alpha), interleukin-6 and F2-isoprostane formation in elderly men. Atherosclerosis. 2005;181(1):201-207.
52. Bermudez EA, Rifai N, Buring JE, Manson JE, Ridker PM. Relation between markers of systemic vascular infammation and smoking in women. Am J Cardiol. 2002;89(9):1117-1119.
53. Woodward M, Rumley A, Tunstall-Pedoe H, Lowe GD. Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol. 1999;104(2): 246-257.
54. Kamath S, Lip GY. Fibrinogen: Biochemistry, epidemiology and determinants. QJM. 2003;96(10):711-729.
55. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101(15): 1767-1772.
56. Walter RE, Wilk JB, Larson MG, et al. Systemic infammation and COPD: The Framingham Heart Study. Chest. 2008;133(1):19-25.
57. Tanaka G, Sandford AJ, Burkett K, et al. Tumour necrosis factor and lymphotoxin A polymorphisms and lung function in smokers. Eur Respir J. 2007;29(1):34-41.
58. Ardlie KG, Lunetta KL, Seielstad M. Testing for population subdivision and association in four case-control studies. Am J Hum Genet. 2002; 71(2):304-311.
59. Allison DB, Heo M, Schork NJ, Wong SL, Elston RC. Extreme selection strategies in gene mapping studies of oligogenic quantitative traits do not always increase power. Hum Hered. 1998;48(2):97-107.
60. Twardella D, Küpper-Nybelen J, Rothenbacher D, Hahmann H, Wüsten B, Brenner H. Short-term beneft of smoking cessation in patients with coronary heart disease: Estimates based on self-reported smoking data and serum cotinine measurements. Eur Heart J. 2004;25(23): 2101-2108.
61. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2004;1; CD003041.
62. Gratziou C. Respiratory, cardiovascular and other physiological consequences of smoking cessation. Curr Med Res Opin. 2009;25(2): 535-545.